Kornimate/medical-research-clean huggingface dataset:
studying tumor tissue samples and blood samples to learn more about dna changes in patients with lung cancer

Conditions: Lung Cancer

Summary: rationale: studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this laboratory study is looking at tumor tissue samples and blood samples to learn more about dna changes in patients with lung cancer.

objectives: * examine the mutational status of the egfr pathway in tumor and blood samples from patients with lung cancer. * correlate the egfr pathway mutations in these samples with clinical outcomes of these patients. outline: archived tumor tissue and blood samples are analyzed via pcr to detect egfr pathway mutations in dna.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed lung cancer patient characteristics: * not specified prior concurrent therapy: * may have received prior egfr inhibitors

Keywords: lung cancer
improvement in copd elderly patients health: study protocol

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: guidelines development, their implementation and the physicians' adherence may have an impact on the occurrence of chronic obstructive pulmonary disease (copd) exacerbations and patient's quality of life. we have developed an educational program based on a checklist to assist general practitioners in managing copd patients. the results of this trial based on electronic health records from big data databases, such as the electronic health record (ehr) of patients from the national health found, associated with checklist, will be directly applicable to primary care in poland and add new data to the growing body of evidence on interventions to improve chronic illness care and patient's quality of life.

this study is the three-arm cluster controlled randomized trial (crt) with the patients nested within practices. the effectiveness of checklist in reduction of copd exacerbations health outcomes in copd patients after 2 interventions will be evaluated and compared to that of usual care. the results of this trial will be directly applicable to primary care in poland and add new data to the growing body of evidence on interventions to improve chronic illness care.

Eligibility criteria:
inclusion criteria: 1. patients: aged 65 years and older with diagnosis of copd registered as j-44 (icd-10). 2. centres: primary health care centers (phcc) with at least 46 copd patients listed. exclusion criteria: none

Keywords: chronic obstructive pulmonary disease (copd) elderly exacerbation of copd prevalence checklist randomized controlled trial electronic health records
the clinical efficacy of different durations of suprascapular nerve pulsed radiofrequency

Conditions: Suprascapular Nerve; Shoulder Impingement Syndrome; Pulsed Radiofrequency; Chronic Pain; Supraspinatus Tendinopathy

Summary: chronic shoulder pain due to impingement syndrome and supraspinatus tendinosis is a debilitating condition. suprascapular nerve innervates most part of shoulder joint. supraspinatus nerve block can be used as a part of pain therapy. however, its efficacy is short-lasting. to prolong analgesia, short bursts of electrical stimulation to suprascapular nerve may be applied. to the date there is no consensus about duration of these type of stimulation. investigators' aim is to investigate efficacy of two different duration of stimulation (pulsed radiofrequency) on chronic shoulder pain.

pulsed radiofrequency (prf) treatment of suprascapular nerve can be used successfully to alleviate pain due to shoulder impingement syndrome and supraspinatus tendinosis. radiofrequency waves produced by radiofrequency (rf) generator through prf modality are applied to suprascapular nerve and create magnetic field. this field leads to pain modulation by changing neuronal activity and resulting in long term depression of pain transmitting nerve fibers. temperature around nerve never exceeds 42 degree and by this way the nerve can be protected from coagulation necrosis and demiyelinisation. prf can be used in the treatment of mixed type nerves such as suprascapular nerve. there are preclinical and clinical studies which report that with longer prf duration, more favorable analgesia. suprascapular prf is performed with 22g, 10 cm, 5 mm active lead rf needle via usg guided posterior approach as institution procotol. howeveri clinicians can choose any duration of prf. instution's pain medicine practitioners hau and geo choose 4 and 9 minutes of prf duration, respectively. investigators' aim is to investigate the efficacy of two different prf duration, 4 and 9 minutes, on shoulder pain and disability index (spadi) and numeric rating scale-11(nrs-11) at 3 month follow-up.

Eligibility criteria:
inclusion criteria: * patients aged 18-80 years * shoulder pain caused by impingement syndrome * shoulder pain due to supraspinatus tendinosis * diagnosis of impingement syndrome and supraspinatus tendinosis confirmed through physical examination and radiological imaging (mri) * pain persisting for 3 months or longer * numeric pain rating scale (nrs) score of 4 or higher despite conservative treatment exclusion criteria: * patients unwilling to participate in the study * presence of chronic pain due to other conditions * presence of cervical radiculopathy * history of opioid use * uncontrolled diabetes (hba1c \> 8) * history of shoulder surgery on the affected side * uncontrolled psychiatric disorders despite medical treatment * history of cancer * history of stroke

Keywords: pulsed radiofrequency suprascapular nerve chronic pain impingement syndrome supraspinatus tendinopathy
predictive factors of ranibizumab treatment in macular edema with crvo

Conditions: Central Retinal Vein Occlusion

Summary: recent studies have shown that intravitreal injection of anti-vegf agent, lucentis (ranibizumab) is effective for macular edema associated with central retinal vein occlusion (crvo). however, there is little information on whether there are any predictive factors of treatment outcome after this treatment. we plan to perform comprehensive functional and imaging tests to determine significant predictive factors.

the purpose of the present study is to investigate predictive factors of treatment outcome after intravitreal injection of lucentis (ranibizumab) in eyes with macular edema associated with central retinal vein occlusion (crvo) using various comprehensive clinical tests including visual filed, spectral-domain optical coherence tomography (sd-oct), ultra wide-field fluorescein angiography, new flicker electroretinogram (erg) using skin electrodes. corrected visual acuity, visual filed, spectral-domain optical coherence tomography (sd-oct), ultra wide-field fluorescein angiography, and new flicker electroretinogram (erg) using skin electrodes are performed before and 3, 6, 9, 12 months after the treatment. predictive factors of treatment outcome are statistically analyzed.

Eligibility criteria:
inclusion criteria: * macular edema associated with central retinal vein occlusion * best corrected visual acuity \< 20/30 * central macular thickness \> 300 * period from symptom onset to treatment \< 12 months exclusion criteria: * any past history of treatment for macular edema (e.g. anti-vegf injection, steroid, vitrectomy)
a study to examine the human papillomavirus types exposure in women from southern africa and brasil

Conditions: HIV; HIV Infections

Summary: this is a study to determine what human papillomavirus hiv seropositive women in botswana, south africa and brasil have been exposed to during their life. the human papillomavirus causes cervical cancer. different types are more likely to lead to cancer than other types. a vaccine has been made to fight infection against hpv 16 and 18 which has been shown to cause cervical cancer in america and europe. what hpv type cause cancer in other countries is not as well studied. hypothesis hpv serology will demonstrate that exposure to each hpv type in gardisil (6,11,16,18) will be \<50% in hiv seropositive women in resource limited countries.

plasma from hiv seropositive women will be taken and sent to merck in the usa to evaluate what the antibody titers of hpv 6,11,16 and 18. .

Eligibility criteria:
inclusion criteria: * hiv seropositive women 18 years of age and older consent signed per local irb requirement exclusion criteria: * can not give blood

Keywords: hpv
spondylodiscitis cases at assiut university hospital

Conditions: Spondylodiscitis

Summary: the term spondylodiscitis (sd) involves infection of the vertebra (spondylitis), infection of the intervertebral disc (discitis), or both (spondylodiscitis) spondylodiscitis is a rare disease accounting for 2.7% of all cases of pyogenic osteomyelitis, with incidence varying from 1 per 100,000/year to 1 per 250,000/year however, there is evidence that the incidence is rising due to longer life expectancy for patients with increasing incidence of chronic debilitating disease including diabetes mellitus, malignancies ,(human immunodeficiency virus (hiv)/ acquired immunodeficiency syndrome (aids) , immunosuppressive therapy, increasing numbers of intravenous drug users , and spinal surgeries. pathogens can reach the spine either by: hematogenous spread, direct external inoculation, or spread from contiguous tissues harboring these pathogens. the hematogenous route is the predominant one, allowing seeding of infection from distant sites into the vertebral column. since spondylodiscitis has not been studied in a clinical trial at our hospital, and information about this disease has come from retrospective case series and isolated cases. in this study, we present our prospectively collected patient clinical and epidemiological data in order to provide a proper management


Eligibility criteria:
inclusion criteria: * all patients who come into assiut university hospital and outpatient clinic with clinical symptoms suggestive of spondylodiscitis in all age groups including patients with known medical conditions and patients who underwent previous spine surgeries (post operative spondylodiscitis) exclusion criteria: * no patients will be excluded
intraoperative radiotherapy in newly diagnosed glioblastoma multiforme

Conditions: Glioblastoma

Summary: intrago ii resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase iii trial which tests if the median progression-free survival (pfs) of patients with newly diagnosed glioblastoma multiforme (gbm) can be improved by the addition of intraoperative radiotherapy (iort) to standard radiochemotherapy.


Eligibility criteria:
inclusion criteria 1. age ≥18 and ≤ 80 years 2. karnofsky performance score (kps) ≥ 60% 3. supratentorial t1-gd enhancing lesion(s) amenable to total resection 4. legal capacity and ability of subject to understand character and individual consequences of the clinical trial 5. patient's written ic obtained at least 24h prior to surgery 6. for women with childbearing potential: adequate contraception 7. patients must have adequate organ functions bone marrow function: * platelets ≥ 75.000/μl * wbc ≥ 3.000/μl * hemoglobin ≥ 10.0 g/dl liver function: * asat and alat ≤ 3.0 times uln * alp ≤ 2.5 times uln * total serum bilirubin \< 1.5 times uln renal function: * serum creatinine ≤ 1.5 times uln inclusion criteria related to surgery: 8. iort must be technically feasible 9. histology supports diagnosis of gbm exclusion criteria 1. multicentric disease (e.g. in both hemispheres) or non-resectable satellite lesions 2. previous cranial radiation therapy 3. cytostatic therapy / chemotherapy for cancer within the past 5 years 4. history of cancers or other comorbidities that limit life expectancy to less than five years 5. previous therapy with anti-angiogenic substances (such as bevacizumab) 6. technical impossibility to use mri or known allergies against mri and/or ct contrast agents 7. participation in other clinical trials testing cancer-derived investigational agents/procedures. 8. pregnant or breast feeding patients 9. fertile patients refusing to use safe contraceptive methods during the study exclusion criteria related to surgery: 10. active egress of fluids from a ventricular defect 11. in-field risk organs and/or iort dose \>8 gy to any risk organ

Keywords: glioblastoma intraoperative radiotherapy radiotherapy dose escalation
non-invasive vagus nerve stimulation for the prevention of migraines

Conditions: Migraine Disorders

Summary: the purpose of the study is to investigate if the use of gammacore sapphire™ device reduces the number of migraines preventatively.

the study is a prospective randomized, multi-center, double-blind, parallel, sham-controlled study, designed for comparison of two parallel groups, gammacore®-sapphire (active treatment) and a sham (inactive) treatment. the study period will begin with a four-week run-in period, during which there is no investigational treatment. the purpose of the run-in period will be to establish a baseline of the subject's headache/migraine history for longitudinal comparison. the run-in period will be followed by a 12-week randomized period when the subjects will be randomized (1:1) to either active treatment or sham (inactive) treatment. subjects will dose themselves 3 times per day for 12 weeks.

Eligibility criteria:
key inclusion criteria: * between the ages of 18 and 75 years * been previously diagnosed with migraine (with or without aura), in accordance with the ichd-3 criteria * experiences between 8 to 20 headaches days per month (during the last 3 months), with at least 5 of them being migraine days * onset of migraine at age 50 years or younger * agrees to refrain from initiating or changing any prophylactic medications for indications other than migraine key exclusion criteria: * concomitant medical condition that will require oral or injectable steroids during the study * currently on a stable regime of more than 1 migraine preventative therapy * other significant pain problem (e.g., cancer pain, fibromyalgia, other head or facial pain disorder) * known or suspected severe cardiac disease (e.g., symptomatic coronary artery disease, prior myocardial infarction, congestive heart failure) * known or suspected cerebrovascular disease * previous cervical vagotomy * currently implanted with an electrical and/or neurostimulator device * been implanted with metal cervical spine hardware or has a metallic implant near the nvns stimulation site * known history or suspicion of secondary headache * currently using marijuana (including medical marijuana) or has used marijuana (including medical marijuana) or cannabidiol oil within the last 6 months * currently takes simple analgesics or nsaids \>15 days per month or triptans, ergots, or combined analgesics \>10 days per month for headaches or other body pain * currently takes prescription opioids more than 2 days per month for headaches or body pain * failed an adequate trial (2 months or greater) of at least 3 classes of a drug therapy for migraine prevention * surgery for migraine prevention * undergone nerve block (occipital or other) in the head or neck within the last 3 months * received botox or cgrp mab injections within the last 6 months * pregnant or thinking of becoming pregnant during the study period, or of childbearing years and unwilling to use an accepted form of birth control * previously used gammacore

Keywords: prevention episodic chronic
development of obesity and bariatric surgery

Conditions: Obesity

Summary: this study focus on the cause of obesity and impacts of bariatric surgery on it.


Eligibility criteria:
inclusion criteria: 1. body mass index ≥18 kg/m2 2. already received bariatric surgery or abdonimal surgery exclusion criteria: 1. acute stroke or acute myocardial infarction in 6 months 2. autoimmune disease 3. long-term use of non-steroidal anti-inflammatory drugs, corticosteroids and immunosuppressive drugs 4. pregnancy 5. consists with other endocrine diseases 6. acute infection in2 weeks 7. cancer 8. use of antibiotics in 3 months 9. chronic digestive inflammations 9

Keywords: obesity
evaluation of use of brain activity monitoring for evaluation of depression treatment

Conditions: Depression

Summary: this study evaluates the use of brain activity monitoring for early identification of pharmaceutical treatment efficacy and development of depression deterioration events.

the study will be conducted in two arms: in arm i, participants diagnosed with depression. in arm ii, healthy participants. arm i - participants that need to start or switch their pharmacological antidepressant therapy will be recruited. their clinical status will be evaluated and their eeg characteristics will be collected. arm ii - clinical and eeg characteristics of healthy volunteers will collected on a similar timetable.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 -70 years (adult, senior) * able and willing to comply with all study requirements. additional inclusion criteria for arm i * diagnosed with depression * being within 2 days of receiving pharmaceutical treatment for depression for the first time or changing dose or changing type of current pharmaceutical treatment or addition to drug of current pharmaceutical treatment. additional inclusion criteria for arm ii brief symptom inventory (bsi \< 2.3). exclusion criteria: the participant may not enter the study if any of the following apply: * diagnosed with psychotic disorder. * diagnosed with central neurological disorder. * a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence. * hearing disorder and/or known ear drum impairment. * high suicide risk as judged by the research team.
hip replacement in a high volume community hospital: effect on length of stay and hospital cost

Conditions: Hip Osteoarthritis

Summary: the investigators propose to evaluate and compare the percentage of patients who are able to be discharged in less than 3 days after undergoing total hip arthroscopy through either a direct anterior or posterior approach, utilizing the identical post operative protocol. the investigators also propose to evaluate the costs associated with the two different approaches to hip replacement in the same group of patients. post operative resource utilization, discharge disposition, and pain medicine requirement will also be evaluated.

the investigators hypothesize that a higher proportion of patients treated with the direct anterior approach for hip replacement will be able to leave the hospital in less than 3 days when compared with a less invasive posterior approach. secondly, decreased length of stay associated with the procedure may reduce hospital costs.

Eligibility criteria:
inclusion criteria: 1. consecutive single surgeon series of patients who have undergone primary uncemented hip replacement at our institution through either a posterior approach or direct anterior approach on a fracture table. posterior approach patient - most recent patient prior to march, 2010, compared with consecutive recent anterior approach patients with minimum of 6 month follow-up. 2. diagnosis of osteoarthritis, inflammatory arthritis, or avascular necrosis. 3. no previous surgery on affected hip. 4. age 40-90 at time of surgery exclusion criteria: 1. patient not permitted to bear full weight after the procedure, per post operative instructions 2. hip replacement performed for acute fracture. 3. previous hip surgery.

Keywords: total hip replacement fracture table depuysynthes direct anterior approach hip replacement posterior approach hip replacement
cohort of respiratory failure patients treated for the first time with non-invasive ventilation at home

Conditions: Respiratory Insufficiency

Summary: the effectiveness of niv is clearly demonstrated but no recent studies describe the prescription based on clinical data and the conditions of using niv at home according the various respiratory diseases. the investigators' purpose is that a better knowledge of niv practices could improve both the quality to support patients at home and the efficacy of the treatment. the main objective of this study is to analyze the clinical data justifying the prescription of niv advice according respiratory disease. the secondary objectives are to study comorbidities, treatment failures, survival rate during the study period.


Eligibility criteria:
inclusion criteria: * no previous experience with domiciliary non-invasive ventilation * adult patients, ≥ 18 years of age * without tracheotomy * no evolutive cancer * no significant psychiatric disease * possible medical monitoring exclusion criteria: * evolutive cancer * inability to understand rationale and/or consent form for study
weight loss and/or exercise training to discover muscle lipids related to insulin sensitivity

Conditions: Diabetes; Pre-diabetes

Summary: the investigators will use exercise training and weight loss to discover localized lipid species related to diabetes risk in people.


Eligibility criteria:
inclusion criteria: * obese men and women with pre-diabetes; (bmi 30-40 kg/m2) * ages ranging from 30-60 years old; * individuals with: * impaired fasting glucose (ifg), (between 100-125mg/dl, with post-prandial glucose (\<140 mg/dl 2 hrs after 75g ogtt) * impaired glucose tolerance (igt), (normal fasting glucose \ 140 mg/dl 2 hrs after 75g ogtt) * a combination of the two (ifg/igt) (both impaired fasting glucose (100-125mg/dl), and impaired glucose tolerance (\>140 mg/dl 2 hrs after 75g ogtt), will be verified using oral glucose tolerance testing at initial screening, and * sedentary (\<2 hours/week of planned physical activity). to increase generalizability, and because each subject serves as their own control, women will be enrolled regardless of menopausal status, use of hormone replacement therapy and oral contraceptives. exclusion criteria: * regular exercise more than 2 hours/week, * medications that could affect glucose, * lipid metabolism, * thyroid disease, * history of lung disease, * pregnancy, * active cigarette smoking or exposure to second hand smoke, and * severe plasma lipid disorders.
the impact of a beach chair position during shoulder arthroscopy on regional cerebral oxygen saturation : comparison of interscalene block and general anesthesia

Conditions: Impaired Oxygen Delivery; Cerebral Hypoxia

Summary: the aim of this study is to investigate the relationship between the patient positioning in the beach chair position with consequential arterial pressure changes and their influence on regional cerebral oxygen saturation under two anesthesia techniques, general anesthesia in one group of patients and interscalene block in the second group of patients.

the participants of the study are patients scheduled for elective shoulder athroscopy. the patients randomise themselves by choosing the type of anesthesia technique (general anesthesia or interscalene block) after detailed description of both techniques. they receive the standard, routine medical care (monitoring and anesthesia techniques) during which the obtained data of arterial pressure, heart rate, peripheral and cerebral oxygen saturation will be statistically analysed and compared.

Eligibility criteria:
inclusion criteria: inclusion criterion for the study was the approval for surgery under general or regional anesthesia with asa i and asa ii patients classification. - exclusion criteria: * the patients who have refused to take part in the study, patients assessed as asa iii or higher, who have cerebrovascular or coronary disease, coagulopathy, hypersensitivity to local anesthetics or other contraindications to one or the other type of anesthetic techniques all patients in whom the operation lasted less than 20 minutes or longer than 90 minutes, have been also excluded from the study.

Keywords: interscalene block, general anesthesia, shoulder arthroscopy, cerebral oxygen saturation, beach chair position